Metyrapone as a Bridging Therapy in Florid Cushing’s Disease Patients Prior to Pituitary Adenomectomy
July 2023
in “
Journal of the ASEAN Federation of Endocrine Societies
”
New to Hydrocortisone? There is a guide in the encyclopedia. Read the guide → Studysummary This case study details the successful use of metyrapone to manage severe Cushing’s disease symptoms and stabilize a patient’s biochemical parameters before she underwent pituitary surgery. Our plain-language summary of this paper — not a Tressless recommendation.
This case study highlights the use of metyrapone as an effective preoperative treatment in a 31-year-old female with florid Cushing's disease, characterized by severe metabolic abnormalities and symptoms such as alopecia and hirsutism. Metyrapone, administered at doses titrated from 250 mg to 500 mg TDS, successfully normalized cortisol levels and improved blood pressure and glucose control, allowing for safer pituitary adenomectomy. The study underscores metyrapone's role in managing severe Cushing's disease when surgery is delayed or rapid cortisol reduction is necessary.
